Some statistical considerations for design of cancer prevention trials
- PMID: 2694163
- DOI: 10.1016/0091-7435(89)90040-6
Some statistical considerations for design of cancer prevention trials
Abstract
Carcinogenesis is believed to occur in at least two stages, initiation and promotion, followed by a preneoplastic lesion which develops into cancer. Cancer prevention trials can be classified as primary if the intervention precedes initiation, secondary if it occurs during promotion, and tertiary if it is applied to a preneoplastic lesion. Tertiary prevention trials resemble treatment trials, but primary and secondary prevention trials may be very different in size, duration, and cost. After reviewing some basic questions which must be addressed in designing any cancer prevention trial, some special design considerations appropriate for primary and secondary prevention trials are discussed. These include the use of factorial designs, group or cluster randomization, special sample size calculations needed for large-scale trials of long duration with cancer incidence as the endpoint, and the idea of the case-cohort approach for monitoring and for subsequent exploratory analysis of trial data.
Similar articles
-
Interpretation of cancer prevention trials.Prev Med. 1989 Sep;18(5):721-31. doi: 10.1016/0091-7435(89)90043-1. Prev Med. 1989. PMID: 2694166 Clinical Trial.
-
The design of cancer prevention trials.Recent Results Cancer Res. 1988;111:34-48. doi: 10.1007/978-3-642-83419-6_5. Recent Results Cancer Res. 1988. PMID: 3175310 No abstract available.
-
On design considerations and randomization-based inference for community intervention trials.Stat Med. 1996 Jun 15;15(11):1069-92. doi: 10.1002/(SICI)1097-0258(19960615)15:11<1069::AID-SIM220>3.0.CO;2-Q. Stat Med. 1996. PMID: 8804140 Review.
-
Design considerations for efficient prostate cancer chemoprevention trials.Urology. 2001 Apr;57(4 Suppl 1):205-12. doi: 10.1016/s0090-4295(00)00976-6. Urology. 2001. PMID: 11295629
-
Accounting for cluster randomization: a review of primary prevention trials, 1990 through 1993.Am J Public Health. 1995 Oct;85(10):1378-83. doi: 10.2105/ajph.85.10.1378. Am J Public Health. 1995. PMID: 7573621 Free PMC article. Review.
Cited by
-
Feasibility of conducting a lung-cancer chemoprevention trial among tin miners in Yunnan, P. R. China.Cancer Causes Control. 1991 May;2(3):175-82. doi: 10.1007/BF00056211. Cancer Causes Control. 1991. PMID: 1873448 Clinical Trial.
-
Intracluster correlation coefficient in multicenter childhood trauma studies.Inj Prev. 2007 Oct;13(5):344-7. doi: 10.1136/ip.2007.015313. Inj Prev. 2007. PMID: 17916893 Free PMC article.
-
Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement.JAMA Netw Open. 2023 Dec 1;6(12):e2346121. doi: 10.1001/jamanetworkopen.2023.46121. JAMA Netw Open. 2023. PMID: 38051535 Free PMC article.
-
Complementary or alternative medicine: the need for plausibility.CMAJ. 2003 Jan 21;168(2):180-2. CMAJ. 2003. PMID: 12538547 Free PMC article. No abstract available.
-
Guidance for protocol content and reporting of factorial randomised trials: explanation and elaboration of the CONSORT 2010 and SPIRIT 2013 extensions.BMJ. 2025 Feb 4;388:e080785. doi: 10.1136/bmj-2024-080785. BMJ. 2025. PMID: 39904527 Free PMC article.